About Fluxion Biosciences
Fluxion Biosciences is a Healthcare company based in San Francisco (United States) founded in 2005, and was acquired by Cell Microsystems in August 2023. Microfluidics-based tools for cellular analysis are provided. Fluxion Biosciences has raised $20.85 million across 9 funding rounds from investors including NIH, HHS and National Cancer Institute. Fluxion Biosciences offers products and services including CellRaft AIR System, BioFlux Systems, CERO 3D Incubator, CASY Cell Counter, and TIGR Tissue Grinder. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Liquid Biopsy. Its competitors include Guardant Health, GRAIL and MaxCyte; 3 of its 3 listed competitors have raised funding.
Company details
Provider of microfluidics-based tools for cellular analysis. It has three main systems which inlcude the IsoFlux Liquid biopsy system uses next-gen sequencing (NGS) to detect somatic variants from circulating tumor cells (CTCs) in blood. Fluxion also provides the reagent kits necessary for analysis with the IsoFlux system. The BioFlux system is a flow-through system that allows researchers to emulate in vivo shear flow conditions during drug discovery. The IonFlux system uses microfluidic technology for automated patch clamping. This system can be used to perform ligand binding, allosteric modulation, multiple agonists, and voltage- and temperature-sensitive assays for ion channel screening in drug discovery.
- Headquarters San Francisco, United States
- Stage Acquired
- SectorsHealthcare
- Website fluxionbio.com
- Social LinkedIn X
- Acquired by Cell Microsystems (Aug 2023)
- Total Equity Funding$20.85M (USD)
in 9 rounds
- InvestorsNIH
& 8 more
- Acquired byCell Microsystems
(Aug 2023)
Products & Services of Fluxion Biosciences
Fluxion Biosciences offers a comprehensive portfolio of products and services, including CellRaft AIR System, BioFlux Systems, CERO 3D Incubator, CASY Cell Counter, and TIGR Tissue Grinder.
Platform for isolating and growing single cells efficiently.
Enables physiological shear flow for drug discovery experiments.
Supports 3D cell culture for organoid and tissue research.
Offers accurate counting and viability assessment of cells.
Facilitates fast, enzyme-free tissue dissociation for analysis.
Funding Insights of Fluxion Biosciences
Fluxion Biosciences has successfully raised a total of $20.85M across 9 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20.85M
- Total Rounds 9
- First Round $6.85M
(Nov 2007)
- Investors Count 8
All 9 funding rounds of Fluxion Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2019 | Grant | – | – | ||
| Oct 2012 | $2M | Series C | – | – | |
| Oct 2011 | $12M | Series C | – | Signet Healthcare Partners | |
| Aug 2009 | $1.8M | Grant | – | – | |
| Aug 2009 | $1.82M | Grant | – | – | |
| Jul 2009 | $200,000 | Grant | – | – | |
| Apr 2008 | $117,700 | Grant | – | – | |
| Apr 2008 | Grant | – | – | ||
| Nov 2007 | $6.85M | Series A | – | Kodiak Venture Partners |
9 investors in total: 9 institutional.
Investors in Fluxion Biosciences
Fluxion Biosciences has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed and early stage venture fund investing in North America and Canada | kodiakvp.com | Waltham, United States | ||
PE firm investing in North America and Europe | signethealthcarepartners.com | New York, United States | ||
Seed and early-stage venture capital firm investing in digital solutions for healthcare and energy industries. | claremontcreek.com | |||
Life sciences startups are funded by a non-profit angel network. | lifescienceangels.com | Sunnyvale, United States | ||
Child health and human development services are provided nationwide. | 1962 | nichd.nih.gov | Bethesda, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of a technology to isolate and recover single cells for molecular analysis | 2009 | cellmicrosystems.com | Durham, United States |
Investor details for Fluxion Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Fluxion Biosciences
2 people are tracked at Fluxion Biosciences (1 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Ali Yehia | VP, Electrophysiology & Drug Screening | Leadership |
Steve Kushman | Manufacturing Manager | Team |
Complete people profiles for Fluxion Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Fluxion Biosciences
4 dated milestones of Fluxion Biosciences across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Fluxion Biosciences is founded.
- Funding First funding round of $6.8M.
- Funding Latest funding round, Grant,.
- Exit Acquired by Cell Microsystems.
Competitors of Fluxion Biosciences
Fluxion Biosciences has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and MaxCyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| maxcyte.com | 1998 | Gaithersburg, United States | $20.69M | 71 | Instrument systems for cell processing and modification are provided. |
Detailed competitors of Fluxion Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Fluxion Biosciences
Websites that share an audience with Fluxion Biosciences (fluxionbio.com).
Websites whose visitors overlap most with Fluxion Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| fluidigm.com | 100% | 1.1K | #14,860,207 | View details | |
| moleculardevices.com | 91% | 131.7K | #329,224 | View details | |
| cellsignal.com | 85% | 488.2K | #114,694 | View details | |
bioflux.com.ro | bioflux.com.ro | 84% | #932,570 | – | |
| nanion.de | 82% | 13.2K | #1,841,615 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 23 similar websites and full traffic analytics for Fluxion Biosciences
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 23 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Fluxion Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Fluxion Biosciences
Complete news archive for Fluxion Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fluxion Biosciences
Fluxion Biosciences was founded in 2005 and raised its 1st funding round 2 years after it was founded.
Fluxion Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Fluxion Biosciences is a funded company, having raised a total of $20.85M across 9 funding rounds to date. The company's 1st funding round was a Series A of $6.85M, raised on Nov 2007.
Provider of microfluidics-based tools for cellular analysis. It has three main systems which inlcude the IsoFlux Liquid biopsy system uses next-gen sequencing (NGS) to detect somatic variants from circulating tumor cells (CTCs) in blood. Fluxion also provides the reagent kits necessary for analysis with the IsoFlux system. The BioFlux system is a flow-through system that allows researchers to emulate in vivo shear flow conditions during drug discovery. The IonFlux system uses microfluidic technology for automated patch clamping. This system can be used to perform ligand binding, allosteric modulation, multiple agonists, and voltage- and temperature-sensitive assays for ion channel screening in drug discovery.
Fluxion Biosciences's top competitors include Guardant Health, GRAIL and MaxCyte.
Fluxion Biosciences offers CellRaft AIR System, BioFlux Systems, CERO 3D Incubator, CASY Cell Counter, and TIGR Tissue Grinder.
Fluxion Biosciences has 9 investors. Key investors include NIH, HHS, National Cancer Institute, Cell Microsystems, and NICHD.
Yes. Fluxion Biosciences was acquired by Cell Microsystems in August 2023.